中文同义词:
一甲基澳瑞他汀 F;一甲基瑞奥西汀F;甲基澳瑞他汀F;一甲基瑞奥西汀F(MMAF);(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲胺基)丁酰胺基)丁酰胺基)-3-甲氧基-5-甲基庚酰)吡咯烷-2-基)-3-甲氧基-2-甲基丙酰胺基)-3-苯基丙酸;一甲基澳瑞他汀F/MMAF/单甲基澳瑞他汀
英文名称:
MonoMethylauristatin F
英文同义词:
MMAF;MonoMethylauristatin F;MonoMethyl Auristatin F | MMAF;MMAF (MonoMethylauristatin F);Monomethyl auristatin phenylalanine;MONOMETHYLAURISTATIN F; MMAF; MONOMETHYL AURISTATIN PHENYLALANINE; 745017-94-1;(2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid;(2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid
相关类别:
科研原药系列;医药原料药;原料药【仅供科研】;原料药
沸点
896.8±65.0 °C(Predicted)
密度
1.116±0.06 g/cm3(Predicted)
酸度系数(pKa)
3.56±0.10(Predicted)
用途
一甲基澳瑞他汀 F用作科学研究和化学试剂等领域。
应用
一甲基澳瑞他汀 F是抗微管药。有力的有丝分裂抑制剂。
用途
MMAF是一种合成的抗肿瘤药物。它是一些实验性抗癌抗体-药物偶联物的一部分,如vorsetuzumab mafodotin和SGN-CD19A。在MMAF-抗体偶联物的国际非专利名称中,mafodotin指的是MMAF及其与抗体的连接结构。MMAF实际上是去甲基奥利斯特汀F;也就是说,N-末端氨基只有一个甲基取代基。
生物活性
MMAF (Monomethylauristatin F) 是一种合成抗肿瘤药,是 tubulin 聚合的有效抑制剂。MMAF(Monomethylauristatin F)可被用作抗体偶联药物(ADCs)中的细胞毒性成分,例如 vorsetuzumab mafodotin,ABT-414和SGN-CD19A。
靶点
Target Value Tubulin ()
体外研究
MMAF inhibits anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O and Caki-1 cells with IC 50 s of 119, 105, 257 and 200 nM in vitro cytotoxicity assay.
体内研究
The maximum tolerated dose in mice of MMAF (Monomethylauristatin F) (>16 mg/kg) is much higher than MMAF (Monomethylauristatin F) (1 mg/kg). cAC10-L1-MMAF 4 has an MTD of 50 mg/kg in mice and 15 mg/kg in rats. The corresponding cAC10-L4-MMAF 4 ADC was much less toxic, having MTDs in mice and rats of >150 mg/ kg and 90 mg/kg in rats, respectively.